Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by RiverPark Advisors LLC

RiverPark Advisors LLC boosted its position in Edwards Lifesciences Co. (NYSE:EW) by 58.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,639 shares of the medical research company’s stock after purchasing an additional 7,583 shares during the period. RiverPark Advisors LLC’s holdings in Edwards Lifesciences were worth $1,362,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in EW. Crewe Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at $28,000. First Community Trust NA purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $29,000. Webster Bank N. A. purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $39,000. Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at $40,000. Finally, Versant Capital Management Inc increased its stake in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 2.4 %

Shares of EW opened at $67.76 on Friday. The stock has a market cap of $39.96 billion, a price-to-earnings ratio of 9.78, a P/E/G ratio of 3.81 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a 50-day moving average price of $67.44 and a two-hundred day moving average price of $76.18.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 earnings per share. Equities analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,250 shares of company stock valued at $2,744,438. Corporate insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of research reports. Citigroup dropped their price target on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research note on Tuesday, October 1st. Barclays dropped their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Oppenheimer reissued an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Finally, Canaccord Genuity Group lowered their target price on shares of Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.